AL
CPRX icon

Airain Ltd’s Catalyst Pharmaceutical CPRX Stock Holding History

Airain Ltd’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-32,575
Closed -$80K – 829
2015
Q4 		$80K Buy
+32,575
New +$93.3K 0.01% 779
2015
Q3 		– Sell
-30,277
Closed -$125K – 878
2015
Q2 		$125K Buy
+30,277
New +$121K 0.01% 806

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Airain Ltd's CPRX Position: Q1 2016 in Review

Airain Ltd sold out of Catalyst Pharmaceutical (CPRX) in Q1 2016, closing a stake of 32,575 shares — an estimated $80K sold.

Airain Ltd first reported a position in CPRX in Q2 2015 and held it in 2 quarters. The position peaked at $125K in Q2 2015. 73 funds tracked by Wall St. Rank hold CPRX as of Q1 2016.

  • Airain Ltd reported no remaining Catalyst Pharmaceutical position as of Q1 2016 after selling out during the quarter.
  • Airain Ltd sold 32,575 Catalyst Pharmaceutical shares in Q1 2016, an estimated $80K.
  • Airain Ltd first reported a position in Catalyst Pharmaceutical in Q2 2015 and held it in 2 quarters.
  • Airain Ltd's Catalyst Pharmaceutical position peaked at $125K in Q2 2015.
  • 73 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2016.

Based on Airain Ltd's 13F filing for Q1 2016, filed 9 May 2016.